Tag: Apeliotus
-
Apeliotus Vision Science’s Readying AdaptDx Product For Roll Out
(www.MacularDegenerations.com) Apeliotus Vision Science is pursuing series A financing worth $4 million in order to advance a product designed to identify the beginning phases of age-related macular degeneration (AMD), reported MEDCITY on August 7. Apeliotus Vision Science Chief Executive Officer John Edwards said in the article focusing on the development that the company is on…